Costs and Consequences of Chronic Kidney Disease in People with Diabetes in Portugal: A Modelling Study
DOI:
https://doi.org/10.20344/amp.22573Keywords:
Diabetes Mellitus, Type 2, Disability-Adjusted Life Years, Health Care Costs, Kidney Failure, ChronicAbstract
Introduction: Chronic kidney disease is the fastest-growing chronic disease in terms of prevalence and one of the biggest causes of global mortality according to the Global Burden of Disease Collaboration. This study aimed to project the natural disease progression of this disease in people with diabetes, and to quantify the costs and consequences in the Portuguese context. This was achieved by developing an analytical model reflecting the epidemiology of chronic kidney disease and integrating the various stages of disease progression.
Methods: A population-based cohort Markov model was used, to follow an adult cohort of people with diabetes and chronic kidney disease as they progressed through different risk categories, in annual cycles, over a period of 50 years. The model considered the natural progression of chronic kidney disease through 18 risk categories based on the KDIGO classification system, as well as the probability of patients receiving renal replacement therapy, including dialysis and kidney transplantation, and the probability of death. Each stage is associated with an annual cost and a disability weight, so the model allowed survival, years lived with disability and lifetime costs to be estimated for the entire population with chronic kidney disease and for patients in different risk categories.
Results: Over the cohort´s lifetime, the model estimated, for the total population with chronic kidney disease and diabetes, an average survival of 8.62 years, with 0.59 years lived with disability, and an average cost of €24 613. These figures correspond to a loss of more than 410 000 years lived with disability and a total lifetime cost of 17.0 billion euros. The progression of this disease was associated with lower survival, more years lived with disability
and higher costs.
Conclusion: The results of this study characterize the natural progression of chronic kidney disease in people with diabetes mellitus type 2, as well as the associated costs and consequences in the national context. Since diabetes mellitus type 2 is a risk factor for chronic kidney disease, it is expected that the real impact will be greater than estimated in the coming decades. Analysis by risk level shows that progression of the disease is associated with worse outcomes.
Downloads
References
Vinhas J, Aires I, Batista C, Branco P, Brandão J, Nogueira R, et al. RENA Study: Cross-Sectional Study to Evaluate CKD Prevalence in Portugal. Nephron. 2020;144:479-87. DOI: https://doi.org/10.1159/000508678
Stevens PE, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, et al. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105:S117-314. DOI: https://doi.org/10.1016/j.kint.2023.10.018
Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12:2032-45. DOI: https://doi.org/10.2215/CJN.11491116
de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305:2532-9. DOI: https://doi.org/10.1001/jama.2011.861
American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2021. Diabetes Care. 2021;44:S15-33. DOI: https://doi.org/10.2337/dc21-S002
Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158:825-30. DOI: https://doi.org/10.7326/0003-4819-158-11-201306040-00007
GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545-602. DOI: https://doi.org/10.1016/S0140-6736(16)31678-6
Eckardt KU, Coresh J, Devuyst O, Johnson R J, Köttgen A, Levey AS, et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet. 2013;382:158-69. DOI: https://doi.org/10.1016/S0140-6736(13)60439-0
Naghavi M, Abajobir AA, Abbafati C, Abbas KM, Abd-Allah F, Abera SF, et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1151-210. DOI: https://doi.org/10.1016/S0140-6736(17)32152-9
Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382:260-72. DOI: https://doi.org/10.1016/S0140-6736(13)60687-X
Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204-22. DOI: https://doi.org/10.1016/S0140-6736(20)30925-9
Foreman KJ, Marquez N, Dolgert A, Fukutaki KB, Fullman N, McGaughey M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018;392:2052-90. DOI: https://doi.org/10.1016/S0140-6736(18)31694-5
Chadban S, Arıcı M, Power A, Wu MS, Mennini FS, Arango Álvarez JJ, et al. Projecting the economic burden of chronic kidney disease at the patient level (Inside CKD): a microsimulation modelling study. eClinicalMedicine. 2024;72:102615. DOI: https://doi.org/10.1016/j.eclinm.2024.102615
KDIGO. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1-150.
Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease – a systematic review and meta-analysis. PLoS One. 2016;11:e0158765. DOI: https://doi.org/10.1371/journal.pone.0158765
Perelman J, Soares M, Mateus C, Duarte A, Faria R, Ferreira L, et al. Methodological guidelines for economic evaluation studies. Lisboa: INFARMED; 2019.
Sociedade Portuguesa de Nefrologia. Gabinete do registo da doença renal crónica da sociedade portuguesa de nefrologia. Lisboa: SPN; 2019.
Nichols GA, Déruaz-Luyet A, Brodovicz KG, Kimes TM, Rosales AG, Hauske SJ. Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes. BMC Nephrol. 2020;21:167. DOI: https://doi.org/10.1186/s12882-020-01792-y
Falcão L, Raimundo M, Fernandes S, Fernandes A, Donato B, Macedo A, et al. At least one hyperkalemia episode is associated with mortality and disease progression in stage 3 CKD patients. J Nephrol. 2023;36:2655-6. DOI: https://doi.org/10.1007/s40620-023-01647-3
Alves Filipe R. Transplantação renal em Portugal. Lisboa: Sociedade Portuguesa de Transplantação; 2022.
Portugal. Despacho n.º 12-A/2020. Diário da República, II Série, 2º Suplemento (2020/01/02). p.165-(2)-(3).
Rocha MJ, Ferreira S, Martins LS, Almeida M, Dias L, Pedroso S, et al. Cost analysis of renal replacement therapy by transplant in a system of bundled payment of dialysis. Clin Transplant. 2012;26:529-31. DOI: https://doi.org/10.1111/j.1399-0012.2011.01571.x
World Health Organization. International statistical classification of diseases and related health problems (10th revision, Volume 1: Tabular list). Genebra: WHO; 2012.
Serviços Partilhados do Ministério da Saúde. (2021). Catálogo de aprovisionamento público da saúde. Lisboa: SPMS; 2021.
Portugal. Portaria n.º 254/2018. Diário da República, I série, n.º 173 (2018/09/07) p.4497-706.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Acta Médica Portuguesa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.
